Study: Combination of Two Immunotherapies Brings Advanced Melanoma Survival Rate up to 50% for First
By combining two existing therapies, researchers found that they have been able to stop or reverse the progression of advanced melanoma.
Study: Combination of Two Immunotherapies Brings Advanced Melanoma Survival Rate up to 50% for First
Calcipotriol/5-FU tx for AKs may reduce future SCC development
Anti-PD-1/bacteria-emulating agent combination for advanced melanoma
Older patients respond better to melanoma immunotherapy
DPCP an option for treatment of patients with melanoma
Macrophages impair PD-1 immunotherapy in melanoma
Blocking demethylase may drive melanoma cells into dormancy
Anti-PD-1/PD-L1 therapy effective for desmoplastic melanoma